Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups. 2013

Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou 510080, China. yanh_liu@163.com.

BACKGROUND The revised 2008 World Health Organization classification maintains a histological grading system (grades 1-3) for follicular lymphoma (FL). The value of grading FL has been debated. This study will yield deeper insights into the morphologic, immunophenotypic characterization and t(14;18) translocation in FL and explore their significance of diagnosis of Chinese FL subgroups. METHODS We retrospectively reviewed the FL diagnoses according to the 2008 WHO classification in all diagnostic specimens from a multicentric cohort of 122 Chinese patients. Upon review, 115 cases proved to be truly FL. CD10, BCL6, MUM1, BCL2 and t(14;18) (q32;q21) translocation were detected by Envision immunostaining technique and fluorescence in situ hybridization. RESULTS FL1 has larger proportion of follicular pattern (93.0%) than that of FL2 (73.7%, P = 0.036), FL3B (63.6%, P = 0.003) and FL3A (77.4%, P = 0.053), although the last P value was more than 0.05 (Pearson's chi-squared test). Areas of DLBCL were present in 25.8% (8/31) of FL3A and more frequent in FL3B (59.1%, 13/22; P = 0.015). The positivity of CD10 and BCL2 in FL1-2 were significantly higher than those in FL3 (P < 0.001, P = 0.043, respectively). The positivity of MUM1 in FL1-2 was significantly lower than that in FL3 (10.2% vs. 51.0%; P < 0.001). Furthermore the positivity of MUM1 in FL3A was significantly lower than that in FL3B (37.9% vs. 68.2%; P = 0.032). The positivity of t(14;18) was higher in FL1-2 than in FL3 (73.5% vs. 35.6%, P < 0.001), and was higher in FL3A than in FL3B (51.9% vs. 11.1%, P = 0.005). t(14;18) was significantly correlated with CD10+ (R = 0.453, P < 0.001) and MUM1+ (R = -0.482, P < 0.001). CONCLUSIONS FL1 and FL2 were immunophenotypically and genomically similar, while FL3A and FL3B were partly immunophenotypically similar but morphologically, genomically distinct. FL3A was genomically closer to FL1-2, whereas FL3A was genomically closer DLBCL. Thus we hypothesize that FL may in fact be a heterogeneous indolent lymphoma encompassing entities with distinct molecular pathogenesis and genetic characteristics. Immunohistochemical and genetic characterization helps to distinguish subgroups of FLs. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1334018129864616.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008224 Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES. Brill-Symmers Disease,Follicular Lymphoma,Lymphoma, Giant Follicular,Lymphoma, Nodular,Follicular Large-Cell Lymphoma,Follicular Lymphoma, Giant,Follicular Lymphoma, Grade 1,Follicular Lymphoma, Grade 2,Follicular Lymphoma, Grade 3,Follicular Mixed-Cell Lymphoma,Giant Follicular Lymphoma,Histiocytic Lymphoma, Nodular,Large Lymphoid Lymphoma, Nodular,Large-Cell Lymphoma, Follicular,Lymphocytic Lymphoma, Nodular, Poorly Differentiated,Lymphocytic Lymphoma, Nodular, Poorly-Differentiated,Lymphoma, Follicular Large-Cell,Lymphoma, Follicular, Grade 1,Lymphoma, Follicular, Grade 2,Lymphoma, Follicular, Grade 3,Lymphoma, Follicular, Mixed Cell,Lymphoma, Follicular, Mixed Lymphocytic-Histiocytic,Lymphoma, Follicular, Mixed Small and Large Lymphoid,Lymphoma, Follicular, Small and Large Cleaved Cell,Lymphoma, Follicular, Small and Large Cleaved-Cell,Lymphoma, Histiocytic, Nodular,Lymphoma, Large Cell, Follicular,Lymphoma, Large Lymphoid, Nodular,Lymphoma, Large-Cell, Follicular,Lymphoma, Lymphocytic, Nodular, Poorly Differentiated,Lymphoma, Lymphocytic, Nodular, Poorly-Differentiated,Lymphoma, Mixed-Cell, Follicular,Lymphoma, Nodular, Large Follicular Center Cell,Lymphoma, Nodular, Large Follicular Center-Cell,Lymphoma, Nodular, Mixed Lymphocytic Histiocytic,Lymphoma, Nodular, Mixed Lymphocytic-Histiocytic,Lymphoma, Nodular, Mixed Small and Large Cell,Lymphoma, Small Cleaved Cell, Follicular,Lymphoma, Small Cleaved-Cell, Follicular,Lymphoma, Small Follicular Center-Cell,Lymphoma, Small Lymphoid, Follicular,Mixed-Cell Lymphoma, Follicular,Nodular Large Follicular Center-Cell Lymphoma,Small Cleaved-Cell Lymphoma, Follicular,Small Follicular Center-Cell Lymphoma,Brill Symmers Disease,Disease, Brill-Symmers,Follicular Large Cell Lymphoma,Follicular Large-Cell Lymphomas,Follicular Lymphomas,Follicular Lymphomas, Giant,Follicular Mixed Cell Lymphoma,Follicular Mixed-Cell Lymphomas,Giant Follicular Lymphomas,Histiocytic Lymphomas, Nodular,Large Cell Lymphoma, Follicular,Large-Cell Lymphomas, Follicular,Lymphoma, Follicular Large Cell,Lymphoma, Follicular Mixed-Cell,Lymphoma, Nodular Histiocytic,Lymphoma, Small Follicular Center Cell,Lymphomas, Follicular,Lymphomas, Follicular Large-Cell,Lymphomas, Follicular Mixed-Cell,Lymphomas, Giant Follicular,Lymphomas, Nodular,Lymphomas, Nodular Histiocytic,Mixed Cell Lymphoma, Follicular,Mixed-Cell Lymphomas, Follicular,Nodular Histiocytic Lymphoma,Nodular Histiocytic Lymphomas,Nodular Large Follicular Center Cell Lymphoma,Nodular Lymphoma,Nodular Lymphomas,Small Cleaved Cell Lymphoma, Follicular,Small Follicular Center Cell Lymphoma
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011237 Predictive Value of Tests In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test. Negative Predictive Value,Positive Predictive Value,Predictive Value Of Test,Predictive Values Of Tests,Negative Predictive Values,Positive Predictive Values,Predictive Value, Negative,Predictive Value, Positive
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D002883 Chromosomes, Human, Pair 14 A specific pair of GROUP D CHROMOSOMES of the human chromosome classification. Chromosome 14
D002887 Chromosomes, Human, Pair 18 A specific pair of GROUP E CHROMOSOMES of the human chromosome classification. Chromosome 18
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis

Related Publications

Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
January 2001, Leukemia & lymphoma,
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
January 2013, Methods in molecular biology (Clifton, N.J.),
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
April 2010, Blood,
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
July 2003, Ceskoslovenska patologie,
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
February 2003, British journal of haematology,
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
November 2003, Leukemia,
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
February 1993, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
April 2013, Human pathology,
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
March 2010, Blood,
Fen Zhang, and Li-Xu Yan, and Su-Xia Lin, and Zi-Yin Ye, and Heng-Guo Zhuang, and Jing-Ping Yun, and Han-Liang Lin, and Dong-Lan Luo, and Fang-Ping Xu, and Xin-Lan Luo, and Jie Cheng, and Ke-Ping Zhang, and Yan-Hui Liu
January 2002, Leukemia,
Copied contents to your clipboard!